article · Arabian Journal for Science and Engineering
Abstract Breast cancer remains a leading cause of cancer-related mortality globally, driving the need for novel effective and less toxic therapeutic agents. This study explores the synthesis and characterization of bioactive compounds: 1-(4-methoxyphenyl)-N-(p-tolyl)methanimine (MPTI), N-(4-methylphenyl)benzamide (MPB), and 4-methyl-N-(p-tolyl)benzenesulfonamide (MTS), and their incorporation into a PMMA/PVP polymer matrix for potential anticancer applications. Morphological analysis of the PMMA/PVP-loaded agents via SEM depicts structural modifications in the PMMA/PVP nanofibrous matrix upon incorporation of the bioactive agents. The FTIR analysis of the synthesized compounds before and after loading into the 7PMMA:3PVP nanofibers reveals successful incorporation of MPTI, MPB, and MTS, with characteristic absorption bands confirming their molecular structures and interactions within the polymeric blend. Moreover, XRD diffractograms showed a transition to an amorphous state upon incorporation of the synthesized compounds into the polymer blend confirming full encapsulation. In vitro release studies showed a sustained release profile of the bioactive agents, with initial burst releases observed over a period of 3 days. Cytotoxicity assays against the MCF-7 breast cancer cell line revealed significant concentration-dependent effects, with MTS exhibiting the highest efficacy. Notably, the PMMA/PVP matrix reduced the cytotoxicity of the formulations, suggesting a protective effect that enhances safety. The findings indicate that the PMMA/PVP system may serve as an effective platform for delivering these bioactive agents for anticancer applications.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1007/s13369-025-10288-6
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.